Hepatorenal syndrome is a severe, functional form of renal failure characterized by marked reductions in renal blood flow and glomerular filtration rate that develops in patients with advanced decompensated cirrhosis or acute-on-chronic liver failure1, 2. It arises from profound circulatory dysfunction and intense renal vasoconstriction rather than structural intrinsic parenchymal injury, making it potentially reversible via medical vasoconstrictor therapy or definitive liver transplantation3, 4.

1. Etiology & Risk Factors

  • Underlying Liver Pathology: Advanced cirrhosis of any etiology (alcoholic, viral, non-alcoholic steatohepatitis) complicated by portal hypertension and clinically significant ascites2, 5.
  • Precipitating Triggers: Spontaneous bacterial peritonitis (SBP), non-SBP bacterial infections, large-volume paracentesis without adequate intravenous albumin replacement, gastrointestinal hemorrhage, and aggressive or inappropriate diuretic administration4, 6.
  • Iatrogenic Insults: Exposure to nephrotoxic agents such as non-steroidal anti-inflammatory drugs (NSAIDs), intravenous radiocontrast media, or aminoglycoside antibiotics in vulnerable cirrhotic patients with depleted effective arterial volume1, 3.

2. Pathophysiology

The pathophysiological cascade of hepatorenal syndrome originates with severe portal hypertension, which induces the local synthesis and release of potent vasodilators (predominantly nitric oxide) within the splanchnic vascular bed4, 5. This results in massive splanchnic arterial vasodilation and peripheral pooling of blood, precipitating a marked decrease in effective arterial blood volume and systemic arterial pressure6. To preserve vital organ perfusion, the body mounts a powerful compensatory response by activating neurohormonal vasoconstrictor cascades, including the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system, and non-osmotic arginine vasopressin release5, 7. While these neurohormonal mechanisms successfully maintain systemic blood pressure temporarily, their effect on the renal circulation is catastrophic, triggering severe, unremitting vasoconstriction of the renal cortical arterioles3, 5. This localized renal ischemia drastically reduces the glomerular filtration rate while preserving tubular integrity initially, which explains the characteristic functional nature of the renal impairment and the absence of cellular casts in the urine1, 4.

Hepatorenal syndrome — Pathophysiological Cascade & Clinical Flowchart 1 Trigger / Primary Insult Portal hypertension and systemic inflammation drive severe splanchnic arterial vasodilation 2 Cellular / Pathophysiological Cascade Effective circulating arterial volume drops, activating neurohormonal vasoconstrictor systems (RAAS, SNS, ADH) 3 Target Organ / Structural Change Intense renal cortical vasoconstriction occurs despite normal renal histology, drastically plummeting the glomerular filtration rate 4 Hallmark Clinical & Diagnostic Manifestation Progressive oliguric AKI develops in decompensated cirrhosis with bland urine sediment and avid sodium retention 5 Complications if Untreated & Therapeutic Target Reversal of renal failure achieved via vasoconstrictor-albumin therapy or definitive liver transplantation

3. Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Rapid or insidious onset of oliguria (urine output less than 400 mL/day), severe fatigue, progressive abdominal distension, peripheral edema, confusion or hepatic encephalopathy, and signs of underlying decompensated liver disease (jaundice, pruritus, hematemesis, or melena)2, 3.
  • Physical Examination & Named Clinical Signs: Markedly distended abdomen with shifting dullness and fluid thrill indicative of tense ascites; prominent caput medusae and spider angiomata; icteric sclerae; asterixis reflecting encephalopathy; bounding peripheral pulses with cool extremities; and the absence of skin rashes or joint effusions that would point toward systemic vasculitis or autoimmune glomerulonephritis4, 5.

4. Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationInternational Club of Ascites (ICA) diagnostic criteria confirmation, showing serum creatinine elevation above 1.5 mg/dL without improvement after 48 hours of diuretic cessation and volume expansion with IV albumin (1 g/kg/day)1, 2.
Laboratory PanelBland urinary sediment with fewer than 50 red blood cells per high-power field, urine protein excretion under 500 mg/day, fractional excretion of sodium (FENa) typically below 0.2%, urinary sodium concentration below 10 mEq/L, and elevated serum bilirubin, international normalized ratio (INR), and model for end-stage liver disease (MELD) score2, 4.
Imaging / Radiology (X-ray, US, CT, MRI)Normal renal ultrasound demonstrating normal kidney size, preserved cortical echogenicity, and the absence of urinary tract obstruction, hydronephrosis, or focal renal parenchymal lesions1, 3.
ECG / Histopathology / ProceduralDiagnostic paracentesis mandatory to evaluate ascitic fluid leukocyte count and exclude spontaneous bacterial peritonitis (neutrophil count >250 cells/mm³); renal biopsy shows normal histology or mild ischemic changes if performed, but is rarely required clinically2, 5.

5. Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
HRS-AKI (Acute Kidney Injury)Defined as an acute increase in serum creatinine of $\ge$0.3 mg/dL within 48 hours, or a percentage increase in serum creatinine of $\ge$50% from baseline known or presumed to have occurred within the prior 7 days; requires urgent medical intervention and vasoconstrictor therapy1, 4.
HRS-CKD (Chronic Kidney Disease)Defined as a static or slowly progressive reduction in estimated glomerular filtration rate ($<60$ mL/min/1.73 m²) for $\ge$3 months in the absence of an acute trigger, reflecting long-standing hemodynamic alterations3, 5.
MELD Score AllocationIntegrates serum bilirubin, serum creatinine, and INR to prioritize patients for urgent liver transplantation evaluation, as medical therapy alone provides temporary bridging2, 7.

6. Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Prerenal AzotemiaResponds rapidly within 24 to 48 hours to volume expansion and absolute discontinuation of diuretics; urine sodium may be low, but renal perfusion recovers completely without persistent oliguria3, 6.
Acute Tubular Necrosis (ATN)Often triggered by severe sepsis, shock, or nephrotoxic drug exposure; presents with muddy brown casts, renal tubular epithelial cells in the urine, a high fractional excretion of sodium (FENa >1-2%), and lack of response to volume expansion or vasoconstrictors4, 7.
Contrast-Induced NephropathyOccurs within 24 to 72 hours following intravascular administration of iodinated radiocontrast media; typically displays a transient peak in serum creatinine with mild tubular injury markers and spontaneous recovery1, 5.
Intrinsic Glomerulonephritis / VasculitisFeatures active urinary sediment with prominent dysmorphic red blood cells, red blood cell casts, significant proteinuria ($>500$ mg/day), and positive specific serological markers (ANA, ANCA, anti-GBM)2, 3.

7. Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Immediate discontinuation of all diuretic therapies, withdrawal of potential nephrotoxic medications (NSAIDs, ACE inhibitors, ARBs), diagnosis and treatment of any underlying bacterial infections (especially spontaneous bacterial peritonitis), and volume expansion with intravenous 20% albumin at 1 g/kg/day (maximum 100 g/day) for 48 hours to rule out simple prerenal azotemia2, 6.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing):
    • Terlipressin: Administered as a continuous intravenous infusion of 2 to 12 mg/24 hours (titrated up by 2 mg increments every 24-48 hours if serum creatinine does not decrease by $\ge$30% from baseline) OR intermittent bolus dosing of 1 mg intravenously every 4 to 6 hours, combined with daily IV 20% albumin (20 to 40 g/day) to maintain central venous pressure and intravascular volume2, 7.
    • Alternative Vasoconstrictors (when terlipressin is unavailable): Intravenous noradrenaline continuous infusion titrated at 0.5 to 3 mg/h to achieve a mean arterial pressure increase of 10 mmHg, combined with daily IV albumin (20 to 40 g/day); OR oral midodrine (7.5 to 12.5 mg TID) plus subcutaneous octreotide (100 to 200 mcg TID) combined with albumin, though evidence shows lower efficacy compared to terlipressin or noradrenaline6, 7.
  • Surgical / Interventional Indications: Evaluation for transjugular intrahepatic portosystemic shunt (TIPS) in selected patients with refractory ascites and early renal impairment to lower portal pressure; urgent referral for definitive orthotopic liver transplantation for all eligible patients failing to respond to medical therapy or presenting with advanced liver failure3, 5.

8. Complications & Prognosis

  • Key Acute and Chronic Complications: Refractory fluid overload, pulmonary edema, severe electrolyte derangements (hyponatremia, hyperkalemia), worsening hepatic encephalopathy, multi-organ dysfunction syndrome, and extremely high short-term mortality without active intervention3, 5.
  • Prognostic Factors & Outcomes: Untreated hepatorenal syndrome carries a dismal prognosis with a median survival measured in weeks to months. Successful response to vasoconstrictor and albumin therapy occurs in approximately 40% to 50% of patients, significantly improving native survival and serving as an effective bridge to definitive liver transplantation, which offers the only long-term cure with 5-year post-transplant survival rates exceeding 60% to 70%2, 7.